Fig. 3

Comparison of clinical progression (Analysis-2, 3). a PFS between patients in the non-anemia-ABI and non-anemia-ADT/CAB groups (Analysis-2) (median, not reached vs. 10.1 months; P < 0.001). b PFS between patients in the anemia-ABI and anemia-AD/CAB groups (Analysis-3) (median, 15 vs. 9 months; P = 0.358). c IPTW adjusted-multivariate Cox regression analyses for PFS of upfront ABI (adjustment for age, ECOG PS, initial PSA, Gleason score, visceral metastasis, EOD, and ALP and LDH levels). Top for the non-anemia patients; (HR, 0.17; 95% CI, 0.07–0.42; P < 0.001). Bottom for the anemia patients; (HR, 0.54; 95% CI, 0.31–1.22; P = 0.186)